22nd Century Group, Inc. Income Taxes Disclosure
NOTE 13. – INCOME TAXES
Pre-tax earnings from continuing operations consisted of the following for the years ended December 31:
| 2025 | | 2024 | |||
Pre-tax income (loss) |
| |
| | ||
U.S. | $ | (13,145) | $ | (15,465) | ||
Outside the U.S. |
| — |
| — | ||
Total pre-tax (loss) earnings | $ | (13,145) | $ | (15,465) | ||
The following is a summary of the components giving rise to the (benefit) provision for income taxes from continuing operations for the years ended December 31:
| 2025 | | 2024 | |||
Federal provision: |
| |
| | ||
Current provision | $ | — | $ | — | ||
Deferred provision |
| (2,650) |
| (3,355) | ||
Change in valuation allowance |
| 2,657 |
| 3,363 | ||
Total federal income tax provision | 7 | 8 | ||||
State provision: |
| |
| | ||
Current provision | (35) |
| 22 | |||
Deferred provision |
| (325) |
| 97 | ||
Change in valuation allowance |
| 325 |
| (97) | ||
Total state income tax (benefit) provision | (35) | 22 | ||||
Foreign provision: |
| |
| | ||
Current provision | — |
| — | |||
Deferred provision |
| — |
| — | ||
Change in valuation allowance |
| — |
| — | ||
Total foreign income tax (benefit) provision | — | — | ||||
Total income tax (benefit) provision | $ | (28) | $ | 30 | ||
The provision for income tax from continuing operations varies from that which would be expected based on applying the statutory federal rate to pre-tax book loss, including the effect of the change in the U.S. corporate income tax rates, as follows:
| 2025 | 2024 | ||||||||||
U.S. federal statutory tax rate |
| $ | (2,760) | 21.0 | % | $ | (3,248) | 21.0 | % | |||
| (28) | 0.2 |
| 17 | (0.1) |
| ||||||
Foreign Tax Effects | ||||||||||||
Canada | — | — | — | — | ||||||||
Effect of changes in tax laws or rates enacted in current period | — | — | — | — | ||||||||
Effect of cross-border tax laws | — | — | — | — | ||||||||
Tax credits | ||||||||||||
Research and development credit carryforward |
| — | — |
| (230) | 1.5 |
| |||||
Changes in valuation allowances | 2,657 | (20.2) | 3,363 | (21.7) | ||||||||
Nontaxable or nondeductible items | ||||||||||||
Stock based compensation (b) |
| 12 | (0.1) |
| 812 | (5.3) |
| |||||
GVB sale adjustments | — | — | (615) | 4.0 | ||||||||
Other | 105 | (0.8) | (80) | 0.5 | ||||||||
Changes in unrecognized tax benefits | — | — | — | — | ||||||||
Other adjustments | (14) | 0.1 | 11 | (0.1) | ||||||||
| $ | (28) | 0.2 | % | $ | 30 | (0.2) | % | ||||
(a) State benefits in Texas made up the majority (greater than 50 percent) of the tax effect in this category. | ||||||||||||
(b) In 2025, incentive stock options not deductible. In 2024, forfeitures of $563, cancellations of $45, and shortfalls of $204. | ||||||||||||
Individual components of deferred taxes consist of the following as of December 31:
| 2025 | | 2024 | |||
Deferred tax assets: |
| |
| | ||
Net operating loss carryforward | $ | 62,743 | $ | 59,605 | ||
Inventory |
| 615 |
| 990 | ||
Stock-based compensation |
| 89 |
| — | ||
Start-up expenditures |
| 102 |
| 124 | ||
Research and development credit carryforward |
| 1,654 |
| 1,654 | ||
Severance liability |
| — |
| 24 | ||
Allowance for credit losses | 102 | 2 | ||||
Research and development costs | 327 | 1,827 | ||||
Operating lease obligations |
| 187 |
| 400 | ||
Capital loss on investment | 2,716 | 2,622 | ||||
Interest expense limitation | 2,775 | 2,259 | ||||
Note payable and warrant liability | — | 373 | ||||
Other |
| 141 |
| 314 | ||
$ | 71,451 | $ | 70,194 | |||
Deferred tax liabilities: |
| |
| | ||
Machinery and equipment |
| (334) |
| (334) | ||
Patents and trademarks |
| (124) |
| (149) | ||
Operating lease right-of-use assets |
| (177) |
| (386) | ||
Other intangible assets |
| (461) |
| (409) | ||
| (1,096) |
| (1,278) | |||
Valuation allowance |
| (70,435) |
| (68,989) | ||
Net deferred taxes | $ | (80) | $ | (73) | ||
The Company has US federal net operating loss (“NOL”) carryforwards of approximately $228,923 as of December 31, 2025 that do not expire. The Company also accumulated US federal NOL carryforward of approximately $46,920 through December 31, 2017 and these NOL carryforwards begins to expire in 2030. In addition to the US federal NOL carryforward, the Company has state NOL carryforwards of approximately $104,844 in various jurisdictions in which it files that will begin to expire in 2031. As of December 31, 2025, the Company has a research and development credit carryforward of approximately $1,654 that begins to expire in 2030. The Company has a capital loss carryover of approximately $11,188 as of December 31, 2025, that begins to expire in 2026. Utilization of these carryforwards may be subject to an annual limitation in the case of equity ownership changes, as defined by law. Due to the uncertainty of the Company’s ability to generate sufficient taxable income in the future, the Company has recorded a valuation allowance to reduce the net deferred tax asset associated with the definite lived assets to zero. These carryforwards are included in the net deferred tax asset that has been fully offset by the valuation allowance. The valuation allowance increased for continuing operations by $2,982 and $3,305 for the years ended December 31, 2025 and 2024, respectively, and changed by ($1,537) and $922 due to tax attributes that were generated as a part of discontinued operations but remain on a prospective basis with continuing operations due to the Company filing a consolidated U.S. federal return for the years ended December 31, 2025 and 2024.
ASC 740 provides guidance on the financial statement recognition and measurement for uncertain income tax positions that are taken or expected to be taken in a company’s income tax return. The Company has evaluated its tax positions and believes there are no uncertain tax positions as of December 31, 2025 and 2024.
The following tax payments and received refunds during the years ended December 31, 2025 and 2024, were as follows:
| 2025 | | 2024 | |||
U.S. federal |
| $ | — |
| $ | — |
State | ||||||
Texas | (32) | 7 | ||||
Georgia |
| (7) |
| 7 | ||
Oregon |
| 2 |
| (2) | ||
New York | — | 10 | ||||
California | — | 3 | ||||
North Carolina | — | (4) | ||||
Other |
| 2 |
| 1 | ||
State Subtotal | $ | (35) | $ | 22 | ||
Foreign |
| |
| | ||
| — |
| — | |||
Total cash paid or income taxes (net of refunds) | $ | (35) | $ | 22 | ||
The One Big Beautiful Bill Act ("OBBB") was signed into law on July 4, 2025. The OBBB makes changes to the U.S. corporate income tax, including immediate expensing of domestic research and development costs, with retroactive application beginning January 1, 2025; reinstating the option to claim 100% accelerated depreciation deductions on qualified property, with retroactive application beginning January 20, 2025; permanent reinstatement of the EBITDA-based limitation for the business interest deduction under IRC Section 163(j); and international tax provisions modifying global intangible low-taxed income ("GILTI"), foreign-derived intangible income ("FDII"), and base erosion and anti-abuse tax ("BEAT"). The impact of the OBBB on the Company is accelerating the expensing of the domestic research and development costs.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 26, 2026 | Showing above |
| 2024 | Mar 20, 2025 | |
| 2023 | Mar 28, 2024 | |
| 2022 | Mar 9, 2023 | |
| 2021 | Mar 1, 2022 | |
About Income Taxes Disclosures
The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.
Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.